Anti-TNF and Crohns Disease: When Should we Start?

Author(s): H. H. Fidder, D. W. Hommes.

Journal Name: Current Drug Targets

Volume 11 , Issue 2 , 2010

Become EABM
Become Reviewer

Abstract:

The natural course of Crohns disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohns disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-α therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNFs and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphomas and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.

Keywords: Crohn's disease, top-down, step-up, tumor necrosis factor-α, immunomodulators, mucosal healing, course of disease, immunosuppression

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 2
Year: 2010
Page: [143 - 147]
Pages: 5
DOI: 10.2174/138945010790309993
Price: $58

Article Metrics

PDF: 8